Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

U.S. launch of Paremyd scheduled for March

Jan. 29, 2002

Naturally occurring angiostatic agents identified by Scripps to have potential in eye diseases

Jan. 28, 2002

Allergan and EntreMed enter five-year strategic alliance in eye diseases

Jan. 24, 2002

Travatan introduced in the U.K.

Jan. 21, 2002

Disappointing preliminary results from first phase III trial of INS-3 Ophthalmic in dry eye

Jan. 17, 2002

Neurotech licenses Amgen's CNTF for ophthalmic indications

Jan. 17, 2002

Disappointing results from phase III trial of SnET2 in wet AMD

Jan. 15, 2002

ISTA files initial section of Vitrase NDA

Jan. 8, 2002

ISV-401 enters phase II trials for bacterial conjunctivitis

Dec. 31, 2001

Muscarinic agonist identified at Acadia reduces intraocular pressure in monkeys

Dec. 28, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...